Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report second quarter 2008 financial results on Monday, August 11, 2008 before the market opens. Inspire’s President and CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host a conference call and live webcast on Monday, August 11, 2008 at 10:00 a.m. ET.
To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 56982011. A live webcast and replay of the call will be available on Inspire’s website at www.inspirepharm.com. A telephone replay of the conference call will be available until August 25, 2008. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 56982011.
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire is currently developing products for dry eye, cystic fibrosis and glaucoma. Inspire employs a U.S. sales force for the promotion of AzaSiteÂ® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, ElestatÂ® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and RestasisÂ® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Inspire Pharmaceuticals, Inc.
Jenny Kobin, 919-941-9777, Extension 219
VP, Investor Relations and Corporate Communications
Dan Budwick, 212-477-9007, Extension 14